$11.7B of 2025 vaccine blockbuster sales lose US exclusivity by 2037, led by Prevnar 20, Gardasil. These 1 public biotech have 2 vaccine treatments in Phase 3 or filed with the FDA, 1 of them already filed.
2025 sales each company reports from tracked vaccine treatments losing US exclusivity by 2037. Big pharma has spent $3.35B on 2 vaccine acquisitions since 2023. See the deals →
VAX-31's 31-valent pneumococcal vaccine thesis hinges on Phase 3 non-inferiority and superiority data against Prevnar 20 and Capvaxive
Filed treatments are listed first. This shows where late-stage treatments are being developed, not which companies will be acquired. Pipeline data and summaries from Readouts as of 29 September 2026; companies already acquired are left out.
Other areas: Oncology · Immunology · Cardiometabolic · Infectious disease · Neuroscience · Other areas